Neurointerventional Devices Market Latest Developments and Innovations Across the Industry

According to a new report from Future Market Insights (FMI), the global Neurointerventional Devices Market will grow at a 4.7% CAGR through 2030. According to the study, the market will be worth $3.6 billion by the end of 2030.

Data Points

Market Insights

Market Value 2021

US$ 2.4 Bn

Market Value 2022

US$ 2.5 Bn

Market Value 2030

US$ 3.6 Bn

CAGR 2022-2030

4.7%

Market Share of Top 5 Countries

72.5%

Key Market Players

Stryker Corporation, Penumbra Inc., Covidien Public Limited,
Johnson & Johnson Private Limited and Terumo Corporation

The prevalence of neurological disorders has more than tripled in recent years. According to the National Center for Biotechnology Information (NCBI), the prevalence of cerebral aneurysm is nearly 3.2%, with women being more likely than men over the age of 50.

It is estimated that approximately 6.5 million people in the United States have an unruptured brain aneurysm, with 30,000 experiencing a rupture each year. Based on these trends, it is not surprising to see the market dotted with the presence of several reputable manufacturers who are constantly launching new products.

Furthermore, the rising prevalence of ischemic stroke is driving the neurointerventional devices market. Because these devices are non-invasive, they increase the chances of survival during surgery, fueling market growth. The market is expected to be worth $3.6 billion by 2030.

Global Neurointerventional Devices Market- Key Takeaways

  • North America shall be the market hegemon, holding a 40.7% market share from 2020-2030

  • Embolic coils to capture the majority share, carotid stents to surge in popularity

  • High incidence of cerebral aneurysm to accelerate adoption of coiling procedures

  • Presence of experienced surgeons shall accelerate hospital-grade neurointerventional device adoption

Scope of the Report

Attribute

Details

Forecast Period

2022-2030

Historical Data Available for

2013-2021

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Western Europe, Eastern Europe,
Japan, APEJ and Middle East and Africa

Key Countries Covered

U.S., Canada, Brazil, Mexico, Germany, France, U.K., Italy, Spain, Nordic,
BENELUX, Russia, Poland, Japan, China, India, ASEAN, ANZ, Rest of Asia Pacific,
GCC Countries, North Africa and South Africa

Key Market Segments Covered

Product, Technique, End User and Region

Key Companies Profiled

• Stryker Corporation

• Penumbra Inc.

• Covidien Public Limited

• Johnson & Johnson Private Limited

• Terumo Corporation

Pricing

Available upon Request

COVID-19’s Impact on the Market
Several hospitals and clinics have reported complications in severely or critically ill patients with co-morbidities due to neurological disorders. COVID-19 may have an effect on both the central and peripheral nervous systems. The virus enters the brain via the olfactory system or a hematogenous route. Once inside, the virus has the potential to cause hypoxia and metabolic abnormalities.

As a result, the neurointerventional devices market is expected to stay afloat in the near term. Since April 2020, there has been a significant increase in mechanical thrombectomies, with the majority of patients seeking treatment for acute strokes caused by large vessel occlusions.

According to a series of case studies conducted on over 200 COVID-19 positive patients in Wuhan, China, 36.4% of patients experienced neurologic symptoms such as acute cerebrovascular events, muscle injury, and impaired consciousness. In this context, the market is primed for a short-term adrenaline rush.

Competitive Intelligence
Stryker Corporation, Covidien Public Ltd., Penumbra Inc., Terumo Corporation, Johnson & Johnson Private Limited, Medtronic PLC, Boston Scientific Corporation, and Abbott are some of the landscape's influential vendors.

Players are emphasising business expansion through partnerships, collaborations, mergers and acquisitions, and participation in trade shows. Many of them are also collaborating with research institutions to expand their research capabilities.

Stryker Corporation successfully launched its Surpass Evolve flow diverter in the US market in August 2020 after receiving FDA clearance. Since 2019, the device has been in use in Europe.

Penumbra Inc. will take part in the virtual Global Embolization Symposium & Technologies 2020 Conference in September 2020. The company hopes to broaden its reach and collaborate with other key players to develop and launch new neurointerventional devices, thereby expanding its current product portfolio.

Browse More@ https://www.futuremarketinsights.com/reports/neurointerventional-devices-market

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Aesthetic Medical Devices Market 2022-2032: Advanced R&D Process Strategies

Image
A recently published study by FMI expects the global  Aesthetic Medical Devices Market  to augment at a 9.6% CAGR from 2022 to 2032. By the end of the said assessment period, a valuation of US$ 35000 Million is expected for the market. The increase may be attributed mostly to the increased development of technologically advanced and user-friendly devices, as well as the rising desire for cosmetic treatments among individuals. In addition to that, the popularity of minimally invasive and non-invasive aesthetic operations is expanding internationally as a result of loose facial skin, particularly around the eyes, jowls, and cheeks; and dry or roughened skin, among other important changes that occur as a person ages. Furthermore, the demand for aesthetic devices is rising due to the growing popularity of cosmetic operations among those seeking to improve their looks and stand out from the crowd. Key Takeaways from the Market Study FMI projects the global aesthetic medical d
Read more